Glucotrack Announces It Has Secured $4M In Funding From Its Leading Shareholder To Support The Upcoming First In Human Clinical Trial Of Its Blood Glucose Monitor
Author: Benzinga Newsdesk | July 31, 2024 04:01pm
Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has secured $4M in funding from its leading shareholder to support the upcoming First in Human clinical trial.
Posted In: GCTK